Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

ABSTRACT: Somatic genetic alterations in cancers have been linked with response to targeted therapeutics by creation of specific dependency on activated oncogenic signaling pathways. However, no tools currently exist to systematically connect such genetic lesions to therapeutic vulnerability. We have therefore developed a genomics approach to identify lesions associated with therapeutically relevant oncogene dependency. Using integrated genomic profiling, we have demonstrated that the genomes of a large panel of human non-small cell lung cancer (NSCLC) cell lines are highly representative of those of primary NSCLC tumors. Using cell-based compound screening coupled with diverse computational approaches to integrate orthogonal genomic and biochemical data sets, we identified molecular and genomic pre

SUBMITTER: Sos ML 

PROVIDER: S-EPMC2689116 | biostudies-literature | 2009 Jun

REPOSITORIES: biostudies-literature